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Background: In patients with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI), unfractionated heparin
(UFH), low molecular weight heparin (LMWH), fondaparinux, or bivalirudin are
treatment options. The relative beneﬁts of each of these regimen merits more sys-
tematic investigation.
Methods: We conducted a Medline/EMBASE/CENTRAL search for randomized
trials (RCT) comparing parenteral antithrombotic therapies for patients undergoing
primary PCI. Five treatment groups were identiﬁed: UFH+Glycoprotein IIbIIIa
inhibitor (GPI), UFH, bivalirudin, fondaparinux or LMWH+GPI. The primary
ischemic outcome was short-term (in-hospital/30-days) major adverse cardiovas-
cular event (MACCE); the primary bleeding outcome was short-term major
bleeding.
Results: We identiﬁed 23 RCTs that enrolled 22899 patients. In the MTC models,
when compared with UFH+GPI, UFH (OR¼1.48; 95% CI 1.18-1.86), bivalirudin
or fondaparinux (numerically higher) were associated with higher MACCE.
Similarly, when compared with LMWH+GPI, UFH (OR¼2.63; 95% CI 1.28-5.26),
bivalirudin (OR¼2.27; 95% CI 1.09-4.76) and fondaparinux (OR¼3.12; 95% CI
1.27-7.69) were associated with a higher MACCE. LMWH+GPI, followed by
UFH+GPI, bivalirudin, UFH and fondaparinux were the hierarchy for treatment
efﬁcacy for MACCE (highest to lowest rank). For bleeding, when compared with
UFH+GPI, both UFH (OR¼0.70; 95% CI 0.55-0.89) and bivalirudin (OR¼0.61;
95% CI 0.47-0.79) were associated with lower major bleeding. Bivalirudin, fol-
lowed by UFH, LMWH+GPI, UFH+GPI and fondaparinux were the hierarchy for
treatment safety (highest to lowest rank). Results were similar in direct comparison
meta-analyses: bivalirudin was associated with a 37% increase in MI, 44% increase
in urgent revascularization, and an 81% increase in stent thrombosis when
compared with UFH or UFH+GPI but with a 43% decrease in major bleeding
when compared with UFH+GPI with no difference when compared with UFH
alone.
Conclusions: In patients undergoing primary PCI, UFH+GPI and LMWH+GPI were
most efﬁcacious with the lowest MACCE rate, whereas bivalirudin was safest with the
lowest bleeding.
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Background: The use of anticoagulants in the setting of acute myocardial infarction
can lead to improvement of short-term survival by costing the increase of bleeding
risk. We performed a meta-analysis of all randomized data that has evaluated the
clinical outcomes among those patients admitted for acute STEMI and that received
either heparin or bivalirudin.
Methods: Pub Med, Chocrane and Scopus were systematically searched up to May
2014. Subjects of analysis were 30 days mortality, AMI, Target Lesion Revascular-
ization, major revascularization, and in-stent thrombosis. We used Fixed or Random
Effect analysis using the Cochrane Handbook of Systematic Reviews.
Results: A total of 3 studies provided a total of 7629 patients, being 3804 in the
bivalirudin group and 3825 patients in the heparin group. There was a strong trend
(p¼0.11) towards decreased AMI in the heparin group, with associated signiﬁcant
decrease of TLR and in-stent thrombosis (p< 0.05). Major bleeding trended towards
the heparin group (Figure 1).
Conclusions: Our analysis suggests that heparin might be associated with better
outcomes at post STEMI event, although there was no mortality beneﬁt. Some of
those beneﬁts might be due to decreased in stent thrombosis. Therefore large ran-
domized studies are warranted.B138 JACC Vol 64/11/Suppl B j SeptemberPharmacotherapy - GPIIb/IIIa inhibitors
Washington Convention Center, Lower Level, Hall A
Saturday, September 13, 2014, 5:00 PM–7:00 PM
Abstract nos: 472-473
TCT-472
Impact of Excess Dosing of Eptiﬁbatide During PCI for ACS: A Pooled Analysis
from the HORIZONS-AMI and ACUITY Trials
Mahesh V. Madhavan1, Philippe Genereux2, Ke Xu3, Ovidiu Dressler3,
Roxana Mehran4, Gregg W. Stone2
1Columbia University Medical Center, New York, NY, 2Columbia University Medical
Center and the Cardiovascular Research Foundation, New York, NY,
3Cardiovascular Research Foundation, New York, NY, 4Icahn School of Medicine at
Mount Sinai, New York, NY
Background: Excess dosing of antithrombotic agents has been associated with
adverse outcomes. To date, dosing errors have not been studied in pts speciﬁcally
undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes
(ACS).
Methods: Analysis was performed in pts who received recommended (labeled
dosing) vs. excess eptiﬁbatide bolus or infusion doses during PCI in the HORI-
ZONS-AMI and ACUITY trials. Adverse outcome rates were assessed. Multivar-
iable analysis was performed to determine predictors of excess dosing and adverse
events.
Results: Of 5,287 pts (840 STEMI, 4,447 NSTEACS) treated with eptiﬁbatide, 543
(10.3%) were administered doses outside the recommended range (including in 319
of 574 pts (56%) with renal dysfunction [creatinine clearance < 50 mL/min].
Predictors of excess dosing included STEMI presentation, baseline creatinine
clearance, baseline hematocrit, and hypertension. Pts who received excess dosing
experienced higher rates of adverse outcomes (Table). By multivariable analysis,
excess dosing was independently associated with 30-day non-CABG major bleeding
(HR [95%CI] ¼ 1.38 [1.05, 1.82], p¼0.02) but not 30-day or 1-year all-cause
mortality (HR [95%CI] ¼ 1.47 [0.79, 2.74], p¼0.22, and 1.26 [0.84, 1.88], p¼0.27,
respectively].
Conclusions: In this large-scale study, excess dosing of eptiﬁbatide during PCI
for ACS was common (even in the clinical trial setting), and was an inde-
pendent predictor of major bleeding but not early or late mortality. Quality
control efforts to ensure proper dosing may improve outcomes in high-risk
ACS pts.13–17, 2014 j TCT Abstracts/Pharmacotherapy - GPIIb/IIIa inhibitors
